Pirfenidone is a medication used for the treatment of idiopathic pulmonary fibrosis. It works by reducing lung fibrosis through downregulation of the production of growth factors and procollagens I and II. A substance that is being studied in the prevention and treatment of scar tissue caused by radiation therapy. It belongs to the family of drugs called anti-inflammatory agents.
Are you looking for or in search of FDA approved “sacituzumab govitecan-hziy for injection in India”? “Medicant Healthcare” a registered pharmacy firm in India deals in both brand name as well as generic name Drugs / medicine approved for Breast Cancer. Need Access of sacituzumab govitecan-hziy injection, get in touch with our healthcare professional.
It was first approved in Japan for the treatment of patients with idiopathic pulmonary fibrosis after clinical trials, under the trade name of Pirespa by Shionogi, in 2008. It was approved for use in the European Union in 2011, in Canada in 2012, and in the United States in October 2014. There is also a topical form named KitosCell developed for the treatment of abnormal wound healing processes
In the European Union, pirfenidone is indicated for the treatment of mild-to-moderate idiopathic pulmonary fibrosis. It was approved by the European Medicines Agency in 2011. In October 2008, it was approved for use in Japan, in India in 2010, and in China in 2011 (commercial launch in 2014). In October 2014, it was approved for medical use in the United States. A tablet version was approved for use in the United States in January 2017.
In Mexico it has been approved on a gel